Study reveals weakness of pharmacies' clinical decision support software in evaluating drug-drug interactions

NewsGuard 100/100 Score

University of Arizona researchers test prescription orders

A study conducted at the University of Arizona College of Pharmacy found that only 28 percent of pharmacies' clinical decision support software systems - the computer programs that are in place to alert pharmacists to possible medication problems - correctly identified potentially dangerous drug-drug interactions.

The study was conducted at 64 pharmacies across Arizona. Members of the research team tested the pharmacy software using a set of prescription orders for a standardized fictitious patient. The prescriptions consisted of 18 different medications that posed 13 clinically significant drug-drug interactions. Of the 64 pharmacies, only 18 correctly identified all of the eligible drug-drug interactions and non-interactions.

"These findings suggest that we have a fundamental problem with the way interactions are evaluated by drug knowledge databases," says Daniel Malone, PhD, UA professor of pharmacy and lead investigator on the study. "The weakness of these systems could lead to medication errors that might harm patients. Pharmacists should become familiar with how their computer system identifies drug interactions. Consumers should always inform their doctor and pharmacist about all medications and other therapies they are using. The risk of harm from dangerous combinations can be reduced when patients create and maintain a medication list."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity showcases cutting-edge solutions at SLAS2024